In 2013, Abraxane (nanoparticle albumin — bound formulation of paclitaxel) was approved in combination
with gemcitabine for metastatic pancreatic cancer.
Influence
of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice.
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the
drug gemcitabine for 6 months resulted in increased overall survival as well as disease - free survival, compared with observation alone, according to a study in the October 9 issue of JAMA.
'' [These] data show that among patients with macroscopic complete removal of pancreatic cancer, the use of adjuvant
gemcitabine for 6 months compared with observation resulted in increased overall survival as well as disease - free survival.
These findings support the use of
gemcitabine in this setting,» the authors conclude.
That allowed tumor cells to survive
gemcitabine treatment in lab dishes and mouse studies, Leore Geller of the Weizmann Institute of Science in Rehovot, Israel, and colleagues discovered.
Giving the mice antibiotics helped
gemcitabine kill tumor cells, increasing the number of tumor cells going through a type of cell death called apoptosis from about 15 percent to 60 percent or more.
They will follow this approach to design a novel treatment plan by rationally
combining gemcitabine with cell cycle checkpoint inhibitor, oxygen - enrich gas inhalation, and radiotherapy to significantly inhibit the growth of aggressive glioma.
Patients were randomly assigned to either
adjuvant gemcitabine treatment for 6 months or to observation alone.
A low, non-genotoxic, dose (about 1 nM) of ActD has been shown to induce a reversible cytostatic effect in normal proliferating dermal fibroblasts and protect them from the aneuploidy induced by the aurora kinase inhibitor VX - 680 and the toxic effects of gemcitabine [46, 47].
Ravid Straussman at the Weizmann Institute of Science in Israel and his team discovered that skin cells infected with Mycoplasma bacteria prevented chemo drug
gemcitabine from killing neighbouring cancer cells.
These experiments were essential to understanding the effect of
gemcitabine on cell cycle and the effective scheduling of checkpoint inhibitor for maximal malignant cell kill.
Of 113 pancreatic ductal adenocarcinoma samples studied, 86
contained gemcitabine - inactivating bacteria.
Adding cisplatin to the
standard gemcitabine / nab - paclitaxel drug treatment provided a very high rate of tumor shrinkage for patients with advanced pancreatic cancer, according to the results of a pilot clinical trial conducted by the HonorHealth Research Institute and the Translational Genomics Research Institute (TGen).
Pemetrexed and
gemcitabine emerged as the top candidates, based in part on their ability to kill group 3 medulloblastoma tumor cells at concentrations that researchers showed were safe and achievable in patients.
Used together, pemetrexed and
gemcitabine doubled life expectancy of mice with human group 3 medulloblastoma, compared to untreated mice.
Researchers used the mice to show that pemetrexed and
gemcitabine worked against human group 3 tumors and that the drugs could be used in combination with existing chemotherapy agents to boost treatment effectiveness without undue risk.
Helmut Oettle, M.D., Ph.D., of the Charite - Universitatsmedizin Berlin, Germany, and colleagues conducted follow - up of a randomized trial that previously reported improvement in disease - free survival with adjuvant (in addition to surgery)
gemcitabine therapy to determine if this treatment improved overall survival.
Wnt / ß - catenin signaling pathway activation
reverses gemcitabine resistance by attenuating Beclin1 - mediated autophagy in the MG63 human osteosarcoma cell line.
Then, in response to the highly abundant ROS in the tumour, the scaffold gradually breaks down,
releasing gemcitabine first, and then anti-PD-L1.
A Phase 1b (Open - Label) / Phase 2 (Randomized, Double - Blinded) Study
Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Extending platinum - free interval with pegylated liposomal doxorubicin, topotecan, or
gemcitabine does not improve overall survival among patients with recurrent ovarian cancer.
Researchers at Haukeland University Hospital in Bergen, Norway have combined a laboratory ultrasound technique called «sonoporation» with the commercially - available chemotherapy
compound Gemcitabine to increase the porosity of pancreatic cells with microbubbles and to help get the drug into cancer cells where it is needed.
For patients who undergo surgery, adjuvant treatment with the chemotherapy drug
gemcitabine lengthens survival.
In the trial one group of patients
received gemcitabine chemotherapy through a drip, as well as a course of IMM - 101 injections.
The team also found that quercetin worked just as well to suppress tumors when used by itself as when it was combined
with gemcitabine, an FDA - approved drug for pancreatic cancer.
The researchers report that these two therapies together represent a highly active combination for refractory or relapsed Hodgkin lymphoma, with a complete response rate exceeding that seen with standard therapy or following administration of either brentuximab vedotin or
gemcitabine alone.
«Our phase 1 trial
combines gemcitabine with two novel cancer immunotherapies — a regimen that has not been tried before,» said Venepalli, a member of the UI Cancer Center.
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic
drug gemcitabine.
In contrast, pretreatment of ActD did not weaken the growth inhibitory effects of VX - 680 in clonogenic assays [46] and did not affect the sensitivity of the tumor cells to gemcitabine [47].
«The finding provides a strong rationale for combination therapy with pemetrexed and
gemcitabine for treatment of group 3 medulloblastoma,» Roussel said.
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months
of gemcitabine - based induction chemotherapy, and assessed the effect of erlotinib on survival.
CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or
gemcitabine in colorectal cancer.
Certain types of bacteria make an enzyme that inactivates the drug
gemcitabine, researchers report in the Sept. 15 Science.
Gemcitabine is used to treat patients with pancreatic, lung, breast and bladder cancers.
In a recent study, working with a team of researchers, Danino demonstrated that bacteria in pancreatic tumors degrade a chemotherapy drug —
Gemcitabine — most commonly used to treat patients who have pancreatic cancer.
This time, she was given different chemotherapy — docetaxel and
gemcitabine — as it was assumed that her cancer had grown resistant to the previous drugs, and, after several weeks, the tumours had shrunk right down.
Findings were presented at the WCLC are based on the updated results of 12 lung cancer patients enrolled in the clinical trial with pembro and irinotecan or
gemcitabine with or without vinorelbine or docetaxel.
The «PembroPlus» clinical trial launched in January 2014 and combines more traditional chemotherapy drugs (
gemcitabine, docetaxel, nab - paclitaxel, vinorelbine, irinotecan, and / or liposomal doxorubicin) with immunotherapy (pembrolizumab), activating the body's own immune system to improve upon results that may be achieved from chemotherapy alone.